Atomo Diagnostics Limited (ASX:AT1)

19.0¢

right-arrow Created with Sketch. -0.005 (-2.56%)
MCAP $110.8M
Last trade 12.32pm 06/12/2021 20mins delayed

Latest Announcements

26/11/2021AT1Atomo Diagnostics Limited
25/11/2021AT1Atomo Diagnostics Limited
10/11/2021AT1Atomo Diagnostics Limited
08/11/2021AT1Atomo Diagnostics Limited
08/11/2021AT1Atomo Diagnostics Limited
28/10/2021AT1Atomo Diagnostics Limited
28/10/2021AT1Atomo Diagnostics Limited
28/10/2021AT1Atomo Diagnostics Limited

Company Overview

Atomo Diagnostics Ltd is an Australia-based medical device company. The Company is engaged in the development and sale of medical devices. Its AtomoRapid is offering rapid diagnostic test (RDT) platform, which provides devices to the global diagnostic market. Its RDT device platforms include Galileo, Pascal, Losev, Newton, Franklin and Elion. It also offers blood-based rapid diagnostic test (RDT) for screening for human immunodeficiency virus (HIV). Its RDT platform includes various features, such as integrated lancelet, blood collection, buffer delivery and digital display. It is also engaged in sales of Atomo branded COVID-19 rapid antibody and antigen tests in Australia.

AT1 in the news

Atomo Diagnostics (AT1) receives approval to supply its HIV Self-Test to a…
Atomo Diagnostics (AT1) and Access Bio are restructuring their commercial relationship to…
Atomo Diagnostics (AT1) is granted FDA clearance for its COVID-19 antibody testThe…
Atomo Diagnostics (AT1), together with Viatris, has agreed to support Unitaid’s quest…

Search Previous Announcements